Wordt geladen...

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache

BACKGROUND: Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repe...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cephalalgia
Hoofdauteurs: Navratilova, Edita, Behravesh, Sasan, Oyarzo, Janice, Dodick, David W, Banerjee, Pradeep, Porreca, Frank
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: SAGE Publications 2020
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7412872/
https://ncbi.nlm.nih.gov/pubmed/32615788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102420938652
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!